Literature DB >> 770511

The effectiveness of diphenhydramine HCI in pediatric sleep disorders.

R M Russo, V J Gururaj, J E Allen.   

Abstract

Fifty children with a variety of sleep disorders were studied in a placebo-controlled, double-blind clinical trial of diphenydramine elixir given in a dosage of 1.0 mg/kg at bedtime. Sleep records measuring latency time, number of awakenings, and duration of sleep were compiled by the patient's parent. A global assessment as to the severity of sleep disturbance and the therapeutic effect of the medication and placebo was made on a weekly basis. Diphenhydramine was significantly better than placebo in reducing sleep latency time and the number of awakenings per night, while sleep duration was marginally increased. There were no essential differences between diphenhydramine and placebo in the other study parameters, i.e., restlessness, nightmares, and difficulty awakening. Diphenhydramine was judged to be more effective than placebo on the weekly global assessment. The results indicate that diphenhydramine is a safe, effective bedtime sleep aid for pediatric patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 770511     DOI: 10.1002/j.1552-4604.1976.tb02406.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

Review 1.  Sleep disorders in children.

Authors:  Oliveiero Bruni; Luana Novelli
Journal:  BMJ Clin Evid       Date:  2010-09-27

2.  Controlled trial of trimeprazine tartrate for night waking.

Authors:  E A Simonoff; G Stores
Journal:  Arch Dis Child       Date:  1987-03       Impact factor: 3.791

3.  Behavior management of infant sleep disturbance.

Authors:  K G France; S M Hudson
Journal:  J Appl Behav Anal       Date:  1990

Review 4.  Insomnia: the Sleeping Giant of Pediatric Public Health.

Authors:  Emily Badin; Cynthia Haddad; Jess Parker Shatkin
Journal:  Curr Psychiatry Rep       Date:  2016-05       Impact factor: 5.285

Review 5.  H1-receptor antagonists. Comparative tolerability and safety.

Authors:  F E Simons
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.